Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1987-04-23
1990-05-22
Griffin, Ronald W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 54, 514 59, 514 60, 514832, 514833, 514921, A61K 3702, A61K 31715
Patent
active
049278061
ABSTRACT:
A highly concentrated solution is provided which is both hyperosmotic and hyperoncotic with respect to blood plasma and has utility in treating patients experiencing or threatening to experience hypodynamic shock. The physiologically acceptable solution comprises a crystalloid to provide a osmolarity in excess of 5000 mOsms and a colloid to provide an oncocity in excess of 200 mm Hg. The solution is easily transported and administered by a single, rapid infusion of about less than about 1 ml/kg of body weight and results in a rapid and sustained normalization of circulatory function.
REFERENCES:
patent: 3864478 (1975-02-01), Bonhard
patent: 3993750 (1976-11-01), Fox, Jr.
patent: 4049795 (1977-09-01), Laborit
patent: 4271144 (1981-06-01), Holly
patent: 4308255 (1981-12-01), Raj et al.
Modig, cited in Biol. Abstracts 78(3) 2473 No. 21745, 1983.
Pristoupil, cited in Chem. Abstracts, vol. 82, 1975, No. 4772b.
Shimazaki, Shuji, et al. Body Fluid Changes During Hypertonic Lactated Saline Solution Therepay for Burn Shock, the Journal of Trauma, 17:38-43, 1977.
Lopes, O. U., Pontieri, V., Rocha, M., Silva, Jr., E., and Velasco, I. T., Hyperosmotic NaCl and Severe Hemorrhagic Shock: Role of the Innervated Lung, Am. J. Physiol 241 (Heart Cir. Physio 20: H883-H890) 1981.
Rush, Jr., B. F., M.D.-Treatment of Experimental Shock: Comparison of the Effects of Norepinephrine, Dibenzyline, Dextran, Whole Blood, and Balanced Saline Solutions, Surgery, vol. 61, No. 6, pp. 938-944 (1967).
Velasco, I. T., Pontieri, V., Rocha E. Silva, Jr., M., and Lopes, O. U., Hyperosmotic NaCl and Severe Hemorrhagic Shock, Am. J. Physiol. 239(5) H664-H673, 1980.
Brooks, D. K.; Williams, W. G.; Morley, R. W.; Whiteman, R., Osmolar and Electrolyte Changes in Haemorrhagic Shock, The Lancet. pp. 521-527, Mar. 9, 1963.
Silbert, Samuel, The Treatment of Thromboangiitis Obliterans, Journal A.M.A. 1759-1761 (Jun. 5, 1926).
Baue, M. D., Arthur E., et al.--A Comparison of Isotonic and Hypertonic Solutions Blood on Blood Flow and Oxygen Consumption in the Initial Treatment of Hemorrhagic Shock, J. of Trauma, vol. 7, No. 5, pp. 743-756 (1967).
Fraser, John; Cowell, E. M., Clinical Study of Blood Pressure in Wound Conditions, Journal A.M.A. Feb. 23, 1918, pp. 520.535, vol. 70, No. 8.
Danowski, T. S.; Winkler, A. W.; Elkinton, J. R.-The Treatment of Shock Due to Salt Depletion; Comparison of the Hemodynamic Effects of Isotonic Saline, of Hypertonic Saline, and of Isotonic Glucose Solutions, J.C.I. 25:130-138 (1946).
Lopes et al.; Chemical Abstracts vol. 96:617p (1982).
Velasco et al.; Chemical Abstracts vol. 93:215562r (1980).
Kramer George C.
Perron Paul R.
Carson Nancy S.
Griffin Ronald W.
The Regents of the University of California
LandOfFree
Saturated salt/concentrated dextran formulation to treat hemorrh does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Saturated salt/concentrated dextran formulation to treat hemorrh, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Saturated salt/concentrated dextran formulation to treat hemorrh will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2134995